Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Journal of Hypertension
|
September 8, 2006
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
George L Bakris, Luis M Ruilope, Stephen O McMorn, et al.
Surgical Endoscopy
|
September 23, 2016
Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm
Karim S Trad, Mark A Fox, Gilbert Simoni, et al.
Psychological Medicine
|
December 4, 2012
Familiality of neural preparation and response control in childhood attention deficit-hyperactivity disorder
B Albrecht, D Brandeis, H Uebel, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2005
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
J Rosenstock, B J Goldstein, A I Vinik, et al.
Environmental Science. Processes & Impacts
|
May 20, 2014
The use of existing environmental networks for the post-market monitoring of GM crop cultivation in the EU
G Smets, E Alcalde, D Andres, et al.
Surgical Innovation
|
April 24, 2014
Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial
Karim S Trad, William E Barnes, Gilbert Simoni, et al.
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement
|
January 1, 1995
Safety assessment of OTC drugs: doxylamine succinate
J A Skare, V A Murphy, R C Bookstaff, et al.
Surgical Innovation
|
February 7, 2018
The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective
Karim S Trad, William E Barnes, Elizabeth R Prevou, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
November 23, 2006
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
G Viberti, J Lachin, R Holman, et al.
Journal of Pharmaceutical Sciences
|
November 1, 1996
Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers
G A Thompson, J V St Peter, M A Heise, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Journal of Hypertension
|
September 8, 2006
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
George L Bakris, Luis M Ruilope, Stephen O McMorn, et al.
Surgical Endoscopy
|
September 23, 2016
Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm
Karim S Trad, Mark A Fox, Gilbert Simoni, et al.
Psychological Medicine
|
December 4, 2012
Familiality of neural preparation and response control in childhood attention deficit-hyperactivity disorder
B Albrecht, D Brandeis, H Uebel, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2005
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
J Rosenstock, B J Goldstein, A I Vinik, et al.
Environmental Science. Processes & Impacts
|
May 20, 2014
The use of existing environmental networks for the post-market monitoring of GM crop cultivation in the EU
G Smets, E Alcalde, D Andres, et al.
Surgical Innovation
|
April 24, 2014
Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial
Karim S Trad, William E Barnes, Gilbert Simoni, et al.
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement
|
January 1, 1995
Safety assessment of OTC drugs: doxylamine succinate
J A Skare, V A Murphy, R C Bookstaff, et al.
Surgical Innovation
|
February 7, 2018
The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective
Karim S Trad, William E Barnes, Elizabeth R Prevou, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
November 23, 2006
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
G Viberti, J Lachin, R Holman, et al.
Journal of Pharmaceutical Sciences
|
November 1, 1996
Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers
G A Thompson, J V St Peter, M A Heise, et al.
Page
of 8